Plain-English translation of NCT04648046 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach called LVgp120duoCAR-T cell therapy for people living with HIV who are already on antiretroviral medications. The treatment involves taking some of your own immune cells (T cells), genetically engineering them in a lab to recognize and attack HIV-infected cells, and then infusing them back into your body. Researchers want to see if this approach is safe and whether it can help reduce the amount of virus in your body.
Even though current HIV medications work well for many people, they require lifelong daily use and don't completely cure the infection. This trial explores whether engineered immune cells could offer a different way to fight HIV, potentially allowing some people to reduce or pause their regular medications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, researchers will first collect some of your blood to isolate your T cells, which will then be sent to a lab for genetic engineering—this process takes several weeks. Once the cells are ready, you'll receive an infusion of your engineered cells at the study center. Depending on which group you're assigned to, you may also receive a conditioning medication () before the cell infusion. Immediately after the infusion, you will stop taking your regular HIV medications, and the research team will closely monitor your health and viral load over the following weeks and months to see how you respond. You'll have regular blood tests and clinic visits to track your safety and how well the treatment is working.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States